Gastrointestinal Cancers

ABSTRACTS

*Duke authors bolded

Predictive and prognostic value of HER2 gene expression and HER2 amplification in patients with metastatic colorectal cancer (mCRC) enrolled in CALGB/SWOG 80405 (Alliance).
SESSION
Gastrointestinal Cancer—Colorectal and Anal
AUTHOR(S)
Francesca Battaglin, Fang-Shu Ou, Xueping Qu, Monica M. Bertagnolli, Howard S. Hochster, Donna Niedzwiecki, Richard M. Goldberg, Robert J. Mayer, Tyler J. Zemla, Charles David Blanke, Alan P. Venook, Omar Kabbarah, Heinz-Josef Lenz, Federico Innocenti
ABSTRACT / POSTER 4086 ● 78

Characterization of sociodemographic and clinicopathological features and associated outcomes of patients (Pts) with anal squamous cell cancer (ASCC): Analysis of 44,084 pts in the National Cancer Database (NCDB).
SESSION
Gastrointestinal Cancer—Colorectal and Anal
AUTHOR(S)
Joanna Alyse Young, Sally Jeanne Trufan, William Mills Worrilow, Laura W. Musselwhite, Reza Nazemzadeh, Kunal C. Kadakia, Seungjean Chai, John Stuart Salmon, Jimmy J. Hwang, Edward S. Kim, Derek Raghavan, Mohamed E. Salem
ABSTRACT / POSTER 4052 ● 44

Disease-free survival as a surrogate for overall survival in neoadjuvant trials of gastroesophageal adenocarcinoma: Pooled analysis of individual patient data from randomized controlled trials.
SESSION
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
AUTHOR(S)
Ulrich Ronellenfitsch, Katrin Jensen, Svenja Seide, Meinhard Kieser, Matthias Schwarzbach, Tracy E Slanger, Bryan Burmeister, David Paul Kelsen, Donna Niedzwiecki, Guillaume Piessen, Christoph Schumacher, Susan Urba, Cornelis J. H. Van De Velde, Marc Ychou, Ralf Dieter Hofheinz, Sylvie Lorenzen
ABSTRACT / POSTER 4533 ● 141

A phase II/III study of perioperative nivolumab and ipilimumab in patients (pts) with locoregional esophageal (E) and gastroesophageal junction (GEJ) adenocarcinoma: A trial of the ECOG-ACRIN Cancer Research Group (EA2174).
SESSION
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
AUTHOR(S)
Jennifer Rachel Eads, Michelle Weitz, Michael K. Gibson, Lakshmi Rajdev, Onkar V Khullar, Steven H. Lin, Constantine Gatsonis, Ignacio Ivan Wistuba, Aravind Sanjeevaiah, Al Bowen Benson, Nathan Bahary, Kristen Renee Spencer, Nabil F. Saba, Stanley R. Hamilton, Charles A. Staley, Anuradha Bapsi Chakravarthy, Terence Z. Wong, Peter J. O'Dwyer
ABSTRACT / POSTER TPS4651 ● 259

Celecoxib in addition to standard adjuvant therapy with 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX) in stage III colon cancer: Results from CALGB/SWOG 80702.
SESSION
Gastrointestinal Cancer—Colorectal and Anal
AUTHOR(S)
Jeffrey A. Meyerhardt, Qian Shi, Charles S. Fuchs, Donna Niedzwiecki, Tyler J. Zemla, Priya Kumthekar, Katherine A Guthrie, Felix Couture, J. Phillip Kuebler, Johanna C. Bendell, Pankaj Kumar, DeQuincy Andrew Lewis, Benjamin R. Tan, Monica M. Bertagnolli, Axel Grothey, Howard S. Hochster, Richard M. Goldberg, Alan P. Venook, Charles David Blanke, Anthony Frank Shields
ABSTRACT 4003

CodeBreak 100: Activity of AMG 510, a novel small molecule inhibitor of KRASG12C, in patients with advanced colorectal cancer.
SESSION
Gastrointestinal Cancer—Colorectal and Anal
AUTHOR(S)
Marwan Fakih, Jayesh Desai, Yasutoshi Kuboki, John H. Strickler, Timothy Jay Price, Greg Andrew Durm, Gerald Steven Falchook, Crystal S. Denlinger, John C. Krauss, Geoffrey Shapiro, Tae Won Kim, Keunchil Park, Andrew L. Coveler, Pamela N. Munster, Bob T. Li, June Kim, Haby Adel Henary, Gataree Ngarmchamnanrith, David S. Hong
ABSTRACT / POSTER 4018 ● 10

FOLFOXIRI/bevacizumab (bev) versus doublets/bev as initial therapy of unresectable metastatic colorectal cancer (mCRC): A meta-analysis of individual patient data (IPD) from five randomized trials.
SESSION
Gastrointestinal Cancer—Colorectal and Anal
AUTHOR(S)
Chiara Cremolini, Carlotta Antoniotti, Alexander Stein, Johanna C. Bendell, Thomas Gruenberger, Gianluca Masi, Elena Ongaro, Herbert Hurwitz, Alfredo Falcone, Hans-Joachim Schmoll, Massimo Di Maio
ABSTRACT / POSTER 4015 ● 7

Olaparib (O) in patients (pts) with pancreatic cancer with BRCA1/2 inactivating mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
SESSION
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
AUTHOR(S)
Eugene R Ahn, Elizabeth Garrett-Mayer, Susan Halabi, Pam K. Mangat, Carmen Julia Calfa, Ajjai Shivaram Alva, Vijay S. Suhag, Omid Hamid, Efrat Dotan, Eddy Shih-Hsin Yang, Olatunji B. Alese, Kathleen J Yost, Alissa S. Marr, Martin Clive Palmer, Forrest L. Thompson, Andrew Lawrence Rygiel, Sarah T. Anderson, Samiha Islam, Richard L. Schilsky
ABSTRACT / POSTER 4637 ● 245

A precision medicine drug discovery pipeline to identify dual CDK2/9 inhibition as a novel treatment for colorectal cancer.
SESSION
Publication Only: Gastrointestinal Cancer—Colorectal and Anal
AUTHOR(S)
Roham Salman Roghani, Ali Sanjari moghaddam, Gabrielle Rupprecht, Erdem Altunel, So Young Kim, Shannon McCall, Beatrice Thomas, Katie Ware, Jason Somarelli, David S. Hsu
ABSTRACT e16056

Brain metastasis from esophageal squamous cell carcinoma: Clinical characteristics and prognosis.
SESSION
Publication Only: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
AUTHOR(S)
Linlin Xiao, Yvonne Marie Mowery, Jun Wang, Min Zhao, Shaowu Jing, Guangbin Gao
ABSTRACT e16525

The natural history of fibroblast growth factor receptor (FGFR)-altered cholangiocarcinoma (CCA).
SESSION
Publication Only: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
AUTHOR(S)
Lipika Goyal, Angela Lamarca, John H. Strickler, Michael Cecchini, Daniel H. Ahn, Islam Baiev, Alice Boileve, Melodie Tazdait, Lindsay Marie Hannan, Jingquan Jia, Hetal Desai Marble, Afsaneh Barzi, Vaibhav Sahai, Jochen K Lennerz, Robin Kate Kelley, Tanios S. Bekaii-Saab, Milind M. Javle, Nataliya Volodymyrivna Uboha, William P. Harris, Antoine Hollebecque
ABSTRACT e16686